Clinical Competition Candidate
FARYDAK
FARYDAK carries substance and product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 23 months away. Active clinical competition may compress the generic entry window.
LOE window
23months
to latest listed patent expiry (June 13, 2028)
Expiry attractiveness: 5/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 156
Phase 2/3 trials: 84
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: PANOBINOSTAT LACTATE
Applicant (NDA holder): SECURA BIO INC
Confidence: High